Broadcast Date: June 11, 2024
Time: 9:00 am PT, 12:00 PM, 18:00 CET
This groundbreaking IPM Live webinar featured a conversation with renowned NCI/NIH researchers and co-authors Wendy Rubinstein and Christos Patriotis as they delve into their new research paper, “Cancer screening with multicancer detection tests: A translational science review.”
This webinar was a revelation for healthcare professionals seeking insights into the potential of MCD tests for early cancer detection.
Here’s what you’ll learn:
- The promise of MCD tests: How these innovative tests can potentially identify various cancers at an early stage, including those lacking established screening methods.
- Benefits and considerations: Explore the potential benefits of MCD tests alongside important factors like test accuracy, overdiagnosis risks, and effective follow-up strategies.
- Real-world results: Gain insights from large-scale studies involving over 16,000 individuals to understand how MCD tests are performing in practice.
- The future of MCD: Discover the key questions researchers are addressing to refine and optimize MCD tests for broader clinical applications.
Don’t miss this opportunity to stay ahead of the curve in cancer detection!
Listen on demand now for the IPM Live webinar featuring Wendy Rubinstein and Christos Patriotis!
Space is limited—reserve your spot today!
A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.
Wendy Rubinstein, MD, PhD
Senior Scientific Officer,
Breast and Gynecologic Cancer Research Group.
Division of Cancer Prevention National Cancer Institute
National Institutes of Health
